
About
Skape Bio builds de novo biotherapeutics for GPCRs using AI-designed compact proteins and high-throughput screening. It works on biologics such as miniproteins and nanobodies, with programs focused on receptor signaling control. The company is based on Danish origins and lists its team and operations from its own platform and about pages.
Services
GPCR-tailored protein design
Designs compact biologics for defined receptor states, epitopes, and mechanisms to control GPCR signaling.
High-throughput in-cell characterization
Maps in-cell expression and full-length receptor binding in human cells for large designed libraries.
Functional pharmacology validation
Advances hits through pharmacology to determine whether molecules activate, block, or modulate receptor signaling.
Biophysics validation
Uses biophysics in-house to support hit validation and program advancement.
Selectivity profiling
Profiles selectivity as part of in-house hit validation and developability work.
Developability optimization
Optimizes hits for production, purification, potency, exposure, stability, and route of delivery.
DMPK tuning
Tunes hits with DMPK work to move them into differentiated programs.
GPCR biologic design
Designs compact biologics for defined GPCR receptor states, epitopes, and mechanisms of action.
2 more services
- High-throughput in-cell screening
- Pharmacology validation
Capabilities
- Assays and studies
- Antibodies
- High-throughput in-cell binding characterization
- Functional pharmacology
- Biophysics
- Selectivity profiling
- Developability
- Developability profiling
- Scale and capacity
- Up to 100,000 designs
- Large encoded libraries
- Therapeutic areas
- GPCR drug discovery
- Membrane proteins
Modalities and species
- Modalities
- Antibody
- Species and models
- Human cells
- Full-length receptors
Industries served
- Biotech
- Biopharma
Details
- Based in
- Copenhagen, Denmark